Back to Research Home
BIOBio-Rad Laboratories Inc
Industrials · Biotechnology: Laboratory Analytical Instruments · Large
$369.95+1.77%
As of 23 Oct 2026Mkt cap $10.4B
Stage 13
AVOID
Fundamentals
32.4/75
Technical
7.2/15
Independent
39.5/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −4.5%
- 3M
- +16.9%
- 6M
- +28.5%
- 1Y
- +10.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 44.8xHist median 20.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 0.5%
- Operating margin
- 10.5%
- FCF margin
- 14.5%
- Current ratio
- 5.6x
Growth
- Revenue growth
- +0.7%Latest FY YoY
- Revenue CAGR
- −3.0%
- EPS CAGR
- −33.3%
- FCF CAGR
- −8.6%
Capital
- Share-count trend
- −3.4%3Y annualised
- Net debt
- $680M1.3x OCF
Annual trend
- CAGR 2021–2025
- −3.0%
- Latest · 2025
- $3B
- YoY
- +0.7%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- headwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded